| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
| Targets |
YB-1[1]
|
|---|---|
| ln Vitro |
SU056 (between 0 and 10 μM, for 48 hours) stops OVCAR3/4/5/8, SKOV3, and ID8 cells from growing [1]. OVCAR-8 and ID8 cell colony formation is dose-dependently inhibited by SU056 (1 μM, 5-8 days) [1]. OVCAR8, SKOV3, and ID8 cells are arrested in sub-G1 and G1 phases by SU056 (1–5 μM, 6 hours) [1]. OVCAR8, SKOV3, and ID8 cell migration is inhibited by SU056 (0-1 μM, 12 hours) [1]. OVCAR8, SKOV3, and ID8 cells undergo apoptosis in response to SU056 (0–5 μM, 24 h) [1]. In OVCAR8 cells, SU056 (1–5 μM, 12 h) suppresses the production of PMSB2, SUMO2, YB-1, and TMSB10 proteins [1]. Paclitaxel (HY-B0015) (0.1, 0.5, and 1 nM) had its cytotoxic effects enhanced by SU056 (0.1, 0.5, and 1 μM, 48 hours)[1].
|
| ln Vivo |
In mice implanted with ID8 cells, SU056 (20 mg/kg, i.p.) reduces the formation of tumors [1]. In immunodeficient mice implanted with ovarian cancer cells (OVCAR8), SU056 (10 mg/kg, intraperitoneal injection, daily) in combination with Paclitaxel (Paclitaxel.html" target="_blank" xstyle="color: #6a4b92; font-weight:bold;">HY-B0015) (5 mg/kg, intraperitoneal injection, weekly) inhibits tumor growth, and the effect is more evident than administration alone [1].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: OVCAR3/4/5/8, SKOV3 and ID8 cells Tested Concentrations: 0-10 μM approximately Incubation Duration: 48 h Experimental Results: Inhibited cell growth with IC50 values of 1.27, 6.8, 4.33, 3.18, 1.73, 3.75 μM. Cell Migration Assay [1] Cell Types: OVCAR8, SKOV3, and ID8 cells Tested Concentrations: 0, 0.5, 1 μM Incubation Duration: 12 h Experimental Results: Dose-dependently inhibited cell migration. Western Blot Analysis[1] Cell Types: OVCAR8 cell Tested Concentrations: 1-5 μM Incubation Duration: 12 h Experimental Results: Dose- dependently inhibited the YB-1, TMSB10, SUMO2, and PMSB2 proteins. |
| Animal Protocol |
Animal/Disease Models: C57BL/6 mice implanted (sc) with luciferase-expressing ID8 cells[1]
Doses: 20 mg/kg Route of Administration: intraperitoneal (ip)injection Experimental Results: diminished the tumor weight by 2-fold, and is well-tolerated. diminished the lung metastases. Inhibited YB-1 expression and downstream MDR1 (IHC assay of tumor sample). |
| References |
| Molecular Formula |
C20H16FNO5
|
|---|---|
| Molecular Weight |
369.343149185181
|
| Exact Mass |
369.101
|
| CAS # |
2376580-08-2
|
| PubChem CID |
155351586
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
27
|
| Complexity |
640
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N1(CCO)C2C(=CC3OCOC=3C=2)C(C2=CC=CC(F)=C2)C2C(=O)OCC1=2
|
| InChi Key |
WVJVLSHRAJOEEW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H16FNO5/c21-12-3-1-2-11(6-12)18-13-7-16-17(27-10-26-16)8-14(13)22(4-5-23)15-9-25-20(24)19(15)18/h1-3,6-8,18,23H,4-5,9-10H2
|
| Chemical Name |
8-(3-fluorophenyl)-2-(2-hydroxyethyl)-5,12,14-trioxa-2-azatetracyclo[7.7.0.03,7.011,15]hexadeca-1(16),3(7),9,11(15)-tetraen-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (135.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (6.77 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 5 mg/mL (13.54 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7075 mL | 13.5377 mL | 27.0753 mL | |
| 5 mM | 0.5415 mL | 2.7075 mL | 5.4151 mL | |
| 10 mM | 0.2708 mL | 1.3538 mL | 2.7075 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
